Individual patient responses vary greatly, as a clinical trial of pregabalin in fibromyalgia shows ( fig 1⇓) . Pain relief is not normally distributed but usually bimodal, being either very good (above 50%) or poor (below 15%). [3] [4] [5] Using averages is unhelpful and misleading, because "average" pain relief is actually experienced by few (if any) patients, and it tells us nothing about how many patients will experience clinically useful pain relief. Research is therefore moving to responder analyses-reporting the proportion of patients achieving outcomes that patients consider worthwhile.
In this article we examine rates of success and failure of drugs used in treating pain. We suggest a radical rethink of achievable analgesic effects, and explore how anticipating and recognising analgesic failure will help improve the management of pain. This approach is relevant to all painful conditions, but here we use examples from acute postoperative pain, headache, and chronic musculoskeletal and neuropathic pain.
Measuring effectiveness
Patients want large reductions in pain intensity (typically at least 50%, ideally no worse than mild pain 6 ), with relief from associated problems such as sleep disturbance and depression but without common adverse events interfering with treatment. Those who get better (responders) do well: recent individual patient analyses for chronic pain interventions have shown that people who respond experience improvements in fatigue, depression, and sleep interference, [7] [8] [9] and general measures of function and quality of life, 8 9 including ability to work. 10 Non-responders have none of these benefits. This message is easy to communicate.
An important feature of responder analysis, reflecting clinical practice, is that everyone who withdraws from a trial for any reason is unequivocally a non-responder: if you don't take the tablet you don't get pain relief. This eliminates the need to assign efficacy results to people no longer in trials and eliminates the considerable bias inherent in the statistical practice of imputing missing data. 11 Imputation methods may be justified in establishing whether interventions have analgesic effects but not when determining clinical effectiveness.
We propose that the scientific assessment of analgesia and the clinical practice of analgesic delivery could be simplified into three guiding principles: measure pain in individual patients, expect analgesic drugs to fail to provide a good response in most patients, and prepare for the next step when failure occurs.
Defining and calculating failure for pain drugs
The table⇓ shows drug specific success and failure rates for postoperative pain, migraine, and chronic musculoskeletal and neuropathic conditions. Data came predominantly from Cochrane reviews or overviews, or individual patient data meta-analyses using sensitive trials in patients with initial pain of moderate or severe intensity. The reviews were done to the highest current standards, 12 avoiding known risks of bias, and with sufficient data to minimise random chance effects. 13 All reviews used a responder definition of at least 50% pain relief or its equivalent. When possible we did not use trials that had imputed data by carrying the last observation forward, but for painful diabetic neuropathy and postherpetic neuralgia, these were the only data available for most drugs. The size of response rates with placebo depends on the outcome (lower placebo rates with tougher outcomes), duration (in chronic pain trials), and pain condition studied. We therefore calculated the maximum possible success as 100%−placebo response and drug specific success as active response−placebo response. The success rate was calculated as a percentage of maximum possible response.
Confronting failure
Drug specific success rates were above 50% for only four drugs in acute postoperative pain (paracetamol 500 mg+ibuprofen 200 mg; paracetamol 1000 mg+oxycodone 10 mg; etoricoxib 120 mg; ibuprofen 400 mg+codeine 26-60 mg) and one in migraine (zolmitriptan 10 mg). For all other drugs and in all other conditions, fewer than half of patients achieved at least a 50% reduction in pain intensity. In acute postoperative pain, the failure rate was 66% with paracetamol 1000 mg and 53% for both ibuprofen 400 mg and diclofenac 50 mg. In migraine, failure rates were 55-71% for most interventions. Failure rates for non-steroidal anti-inflammatory drugs were 58-72% in ankylosing spondylitis, ≥70% in osteoarthritis, and ≥80% in chronic low back pain. For neuropathic conditions, antidepressants and antiepileptics had failure rates of ≥70% in painful diabetic neuropathy and postherpetic neuralgia, and ≥87% in fibromyalgia. Data for opioids in chronic non-cancer pain were available only for tapentadol and oxycodone in a combined analysis of osteoarthritis and chronic low back pain trials; tapentadol had a failure rate of 90% and oxycodone had a failure rate of 100%, consistent with what is seen with other analyses for conventional strong opioids.
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Reflecting on failure
The magnitude of the failure to achieve good pain relief, especially over the longer term in chronic pain, is sobering. The high failure rates are a consequence of using patient centred definitions of benefit combining high level of pain relief with tolerable adverse events, using higher standards of evidence, and avoiding major imputation bias. These higher standards are backed by considerable evidence supporting their validity.
Use of responder analysis changes judgments of benefit and risk. With failure, patients without benefit should be exposed to no risk because the drug is stopped; only effective drugs should continue to be prescribed. With success, considerable benefits in terms of pain relief, sleep, fatigue, depression, function, and quality of life are balanced against rare risk of serious harm. Average benefits have no part in these discussions. The good news is that success is often achieved within the first two weeks or so of treatment or not at all, 14 15 and when achieved, tends to last.
Classic clinical trials, providing almost all our evidence in chronic pain, may underestimate efficacy. Fixed dose regimens may exacerbate adverse events and withdrawals, resulting in higher failure rates. An alternative approach is to allow patient directed titration to achieve adequate pain relief with tolerable adverse events; only those with treatment success are then randomised blindly between continuing therapy and placebo. Such trials, known as enriched enrolment randomised withdrawal trials, have lower failure rates. In fibromyalgia, titrating pregabalin to an effective dose resulted in good drug specific pain relief lasting six months in 15% of the original population of patients; the overall failure rate was only 85% compared with over 90% in classic trials. 16 Drug therapy is rarely the only treatment used in chronic pain, but clinical trials designed for regulatory purposes force us into considering single interventions. Randomised withdrawal trials may reflect the real world more accurately and be a better test, but with only a single example this is speculation.
Pragmatic approach
The principles of treatment should be to measure pain, expect and recognise analgesic failure, and to react to it, pursuing analgesic success rather than blindly accepting failure. In any condition, the order in which analgesics should be tried is predicated on efficacy and safety, and adjusted for individual patient characteristics.
A pragmatic implication of high failure rates is that populations with pain need access to a broad range of drugs to have a better chance of success (box). The problem is the dearth of data to help devise starting, stopping, and switching rules. Currently, we have no good evidence from clinical trials that switching is successful in pain; we have a single study of limited methodological quality 17 and a suggestion of differences between closely related tricyclics. 18 Switching drugs works in other conditions, like depression, where randomised trials show that while drugs used individually benefited fewer than half of patients, the majority benefited when failure was followed by another drug. 19 20 Guideline developers often restrict treatment options to one or two drugs (such as, the NICE neuropathic pain guideline 21 ). They consider similar drugs to operate as a class, and so select one as the first or only option despite possibly important differences in pharmacokinetics or drug interactions. Less restrictive guidance, centred on patient-clinician interaction and a large dose of clinical wisdom as well as evidence, may do better; the NICE osteoarthritis guidance comes close. 22 Regulatory authorities also need to recognise that failure is the norm. European regulators, unlike their US counterparts, have refused to license any drug in fibromyalgia because of inadequate average effect size, ignoring the fact that these drugs work well (≥50% reduction in pain intensity) in around 10% of patients with this difficult to treat condition. New drugs are unlikely to be much better. A change in regulatory attitude is overdue, would be sensible, and will benefit patients.
Clinical trial design
Chronic pain conditions are complex and associated with considerable comorbidity. Coupled with the intricacies of pain modulation, central nervous system changes, and genetic influences, high failure rates with single interventions are unsurprising. The new game in town is specificity of effect for specific targets, but with only a small percentage of patients benefiting. Randomised withdrawal designs seem promising, 23 but there are few good examples, and they are not always accepted or understood. New designs are also important for non-drug interventions that produce substantial benefits in few patients, including complementary therapies.
We need to determine how best to use the interventions we have to provide better care for more people at lower cost. Clinical effectiveness trials could be one way forward. 24 They should inform stopping and switching rules to underpin best practice; outlines of informative pragmatic designs are available, building on examples from other chronic diseases. 24 For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
Practical implications of high failure rates
• No single drug will treat successfully more than a minority of patients with a painful condition
• Successful pain relief is also likely to improve sleep, depression, fatigue, quality of life, function, and ability to work
• Experience (and some evidence) suggests that failure with one drug does not necessarily mean failure with others, even within a class
• We do not know the best order in which to use drugs, in terms of efficacy, harm, or cost
• Success or failure can be determined within 2-4 weeks, and success, when achieved, tends to be long lasting
• Because success rates are low, a wide range of drugs is needed to do the best for most patients, especially in complex chronic conditions
Conclusion
Embracing high failure rates is the first step to doing better with what we have. Pronouncing about the importance of failure is rare in science. We believe that pain medicine has now reached a degree of maturity where it can confront its failings. We propose a radical transformation in how we establish analgesic efficacy and harm. Clinically this means expecting analgesic failure, assessing pain, and understanding options for stopping and switching. For the drug industry, regulators, and researchers this means casting aside our slavish reliance on the average, and asking what works for whom in what circumstance, recognising that population improvements in overall effect will require access to numerous treatment options to achieve pain relief for the individual.
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